Business Context and Reporting Period
Company: Adagio Medical Holdings, Inc. (ADGM)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2025
Business Overview: Adagio is a clinical-stage medical device company developing Ultra-Low Temperature Ablation (ULTA) technology for treating cardiac arrhythmias, specifically ventricular tachycardia (VT). The company's primary product candidate is the vCLAS Cryoablation System, which holds CE Mark approval in Europe and has received FDA Breakthrough Device Designation. In October 2025, the company completed enrollment in its FULCRUM-VT pivotal IDE study in the U.S. and Canada.
Key Financial Metrics
| Metric | 2025 (Full Year) | 2024 (Full Year) |
|---|---|---|
| Revenue | $0 | $0.6 million |
| Net Loss | $(25.1) million | $(75.0) million |
| Operating Loss | $(21.9) million | $(84.2) million |
| Cash and Cash Equivalents (Dec 31) | $17.1 million | $20.6 million |
| Accumulated Deficit | $(95.6) million | $(70.6) million |
| Convertible Notes Payable (Fair Value) | $21.0 million | $17.2 million |
| Weighted Average Shares Outstanding | 16.6 million | 14.8 million |
Note: 2024 figures include significant non-cash impairment charges ($30.3M goodwill, $18.9M intangibles) and fair value adjustments related to the SPAC business combination completed in July 2024.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to zero in 2025 compared to $0.6 million in 2024. This was due to a strategic realignment in February 2025 to prioritize the FULCRUM-VT clinical trial, resulting in a pause of the limited European commercial launch and an inventory buyback.
- Reduced Net Loss: The net loss decreased significantly from $75.0 million in 2024 to $25.1 million in 2025. The 2024 loss was inflated by one-time impairment charges totaling $49.2 million and large fair value gains on warrant liabilities ($6.6 million) that did not recur in 2025.
- Operating Expenses: Total operating expenses decreased by 16% to $21.9 million in 2025. Selling, General, and Administrative (SG&A) expenses dropped 47% due to the absence of SPAC-related transaction costs and lower headcount. Research and Development (R&D) expenses decreased 13% to $10.6 million.
- Financing Activity: In October 2025, the company closed a private placement (2025 PIPE) raising approximately $19 million in gross proceeds through the sale of common stock, pre-funded warrants, and milestone warrants.
Guidance, Outlook, and Risks
- Clinical Outlook: The company plans to present six-month primary efficacy results from the FULCRUM-VT trial at the Heart Rhythm Society 2026 Conference in April 2026. An application for FDA approval of the vCLAS system is targeted for the first half of 2026.
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. As of the filing date, cash resources ($17.1 million) are not sufficient to fund operations for the next 12 months. The company estimates it can fund operations into the third quarter of 2026 based on current plans.
- Capital Needs: The company expects to require additional capital to fund clinical activities, manufacturing, and commercialization. Future funding may come from equity or debt offerings, which could result in dilution.
- Key Risks:
- Regulatory Approval: Failure to obtain FDA approval for the vCLAS system would prevent U.S. commercialization.
- Liquidity: Inability to raise additional capital could force the suspension of clinical trials or operations.
- Debt Obligations: The company has $20 million in Convertible Securities Notes (13% interest, maturing April 2028) which are convertible at $10.00/share. Default could lead to acceleration of debt or forced conversion.
- Market Acceptance: Success depends on physician adoption and reimbursement coverage, which are not guaranteed.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure additional financing before Q3 2026 to avoid insolvency.
- Clinical Data: Monitor the April 2026 release of FULCRUM-VT six-month results for safety and efficacy endpoints (freedom from VT, major adverse events).
- Debt Terms: Review the covenants and conversion mechanics of the $20 million Convertible Securities Notes and the impact of potential dilution.
- Commercial Strategy: Assess the timeline and strategy for U.S. commercial launch post-FDA approval, given the current pause in European sales.
- Going Concern Opinion: Review the auditor's report regarding the "substantial doubt" qualification and management's specific mitigation plans.